Pfizer Inc. $PFE Shares Bought by Bank of Jackson Hole Trust

Bank of Jackson Hole Trust raised its stake in Pfizer Inc. (NYSE:PFE) by 18.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,816 shares of the biopharmaceutical company’s stock after purchasing an additional 1,854 shares during the quarter. Bank of Jackson Hole Trust’s holdings in Pfizer were worth $286,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the 1st quarter valued at $27,000. Curio Wealth LLC raised its stake in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the period. North Capital Inc. purchased a new position in shares of Pfizer in the 1st quarter valued at $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer during the 1st quarter worth $28,000. Finally, Harbor Asset Planning Inc. purchased a new stake in Pfizer during the 2nd quarter worth $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 1.0%

Pfizer stock opened at $24.53 on Wednesday. The firm has a market cap of $139.44 billion, a PE ratio of 13.05, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm’s 50 day moving average price is $24.84 and its two-hundred day moving average price is $24.23. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.17.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Morgan Stanley dropped their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.